



# A Study of avutometinib (VS-6766) and cetuximab in Patients with Advanced Colorectal Cancer

## Study Overview:

The purpose of this research is to gather information on the safety and effectiveness of avutometinib (VS-6766) in combination with cetuximab. Doctors leading this study want to find out if combining two medications (cetuximab and VS-6766) is better or worse than the usual approach for the treatment of colorectal cancer. The usual approach for treating colorectal cancer after it progresses involves chemotherapies like fluorouracil (5-FU), oxaliplatin, irinotecan and possibly a medication like bevacizumab. This study will instead combine cetuximab and VS-6766 to find out if the two medications can help people living with advanced colorectal cancers with certain mutations (differences) called KRAS mutations.

This is an open-label trial. Every patient will be treated with active study drugs, and their investigator will not be comparing it to a placebo. Avutometinib is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA). The FDA has approved cetuximab as a treatment option for head, neck and colorectal cancers.

**Study (Protocol) Title:** A Phase 1b/2 Study of avutometinib (VS-6766) and cetuximab in Patients with Advanced KRAS Mutated Colorectal Cancer

**Study (Protocol) Numbers:**

Verastem ID: IST-VS-6766-004

Clinical Trial: NCT05200442

**Study Drugs or Compounds:** avutometinib (VS-6766) and cetuximab

**Study Phase:** Phase 1/2

**Total Enrollment:** estimated at 42 patients

**Sponsor:** University of Chicago (UChicago)

**Collaborators:** Verastem Oncology

**Principle Investigator:** Ardaman Shergill